Safety profile across phase 3 trials
Most AEs seen with KRYXANA were mild to moderate in severity
Majority of AEs were predictable, manageable and reversible. 1-4 .
...
Most AEs seen with KRYXANA were mild to moderate in severity
Majority of AEs were predictable, manageable and reversible. 1-4 .
...
PROGRESSION FREE SURVIVAL (PFS) PER INVESTIGATOR ASSESSMENT
Rapid and sustained first-line efficacy with an AI 1
ORR was 54.5% (95% CI: 48.4-60.6) in the KRYXANA arm vs 38.8% (95% CI:...
OVERALL SURVIVAL (KRYXANA + NSAI + goserelin subgroup) 1,2
ITT: Superiority was established for overall survival. KRYXANA is not indicated for concomitant use with tamoxifen. P=0.00973 (HR=0.712 [95% CI: 0.535-0.948]).
...
OVERALL SURVIVAL 1,2
Overall survival significantly improved in postmenopausal women with a 28% reduction in risk of death
P =0.00455 (HR=0.724 [95% CI: 0.568-0.924])
PROGRESSION FREE...
OVERALL SURVIVAL (ITT) 1,2
Overall survival significantly improved in postmenopausal women with a 28% REDUCTION IN RISK OF DEATH
P=0.00455 (HR=0.724 [95% CI: 0.568-0.924])
Results reported at 42...
Optimize outcomes with early monitoring 1
Multiple guidelines recommend ongoing monitoring as part of routine follow-up care for metastatic Breast Cancer
The European Society for Medical Oncology (ESMO)...In case you may have missed webinars related to KRYXANA, we have the recordings available for some
Year 2021
...
Explore how KRYXANA is different from other CDK 4/6 inhibitors
All CDK 4/6 inhibitors are different.
CDK 4 vs CDK 6 inhibition with KRYXANA 1
Data derived from 2 separate studies that assessed all...
KRYXANA is the only CDK 4/6 inhibitor that offers adjustable dosing without the need for a new prescription mid-cycle.1 This makes inventory management simpler for pharmacists as well as for clinicians and patients if there is a need for dose...